Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 7/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CCR9 | P51686 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126509 | 0.92 | RIPK1 (0.37) | RIPK1NAMPTNOTUMMDM2ALDH1A1 | |
| SCHEMBL4136915 | 0.91 | NAMPT (0.37) | NAMPTALDH1A1SMN1; SMN2RXRAGRIN1 | |
| SCHEMBL4135640 | 0.91 | NAMPT (0.37) | NAMPTP2RX7ALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL4135868 | 0.91 | NAMPT (0.39) | NAMPTALDH1A1SMN1; SMN2KMT2AEPHX2 | |
| SCHEMBL3704869 | 0.90 | P2RX7 (0.37) | NAMPTP2RX7KMT2ARORCEPHX2 | |
| SCHEMBL4123666 | 0.89 | ALDH1A1 (0.38) | RIPK1NAMPTNOTUMMDM2ALDH1A1 | |
| SCHEMBL4125823 | 0.89 | NAMPT (0.38) | NAMPTP2RX7EPHX2PTGS2 | |
| SCHEMBL4130432 | 0.88 | NAMPT (0.39) | RIPK1NAMPTALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL4129210 | 0.87 | P2RX7 (0.37) | NAMPTP2RX7ALDH1A1SMN1; SMN2PTGS2 | |
| SCHEMBL4118159 | 0.86 | GAA (0.35) | RIPK1NAMPTALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | RIPK1 4203/4885NAMPT 2129/4885P2RX7 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.